anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Pregnancy — Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during therapy. Fluoxetine capsules, USP should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus [see Use in Specific Populations (8.1)].

Nursing Mothers — Patients should be advised to notify their physician if they intend to breast-feed an infant during therapy. Because fluoxetine is excreted in human milk, nursing while taking fluoxetine capsules, USP is not recommended [see Use in Specific Populations (8.3)].

Pediatric Use of Fluoxetine Capsules, USP — Fluoxetine capsules, USP is approved for use in pediatric patients with MDD and OCD [see Box Warning and Warnings and Precautions (5.1)]. Limited evidence is available concerning the longer-term effects of fluoxetine on the development and maturation of children and adolescent patients. Height and weight should be monitored periodically in pediatric patients receiving fluoxetine. [see Warnings and Precautions (5.6) and Use in Specific Populations (8.4)].

Information for pediatric patients (10 to 17 years) is approved for Eli Lilly and Company’s Fluoxetine Capsules. However due to Eli Lilly and Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
Present disclosure relates to a patient response device. Patient response device includes: a processor controlling operations of patient response device, a network interface controller facilitating communication among patient response device, an emergency response system server and a communication system of an emergency response system, an emergency medicine storage, and a non-volatile memory. Emergency medicine storage includes one or more emergency medicine compartments for storing one or more patient specific emergency medicines for patients. Non-volatile memory stores an operating system, a GPS module for detecting GPS location of patient carrying patient response device, and a patient response device controller. Patient response device controller includes: a patient information storage module, a patient communication control module, and computer executable instructions. Patient information storage module stores patient's information. Patient communication control module facilitates communication through the network interface controller to the emergency response system server and the communication system over a communication network.
The invention provides a preparation method and bacteriostatic activity study of a voriconazole copper complex. The synthetic method includes: dissolving voriconazole (called FZ for short) and copper sulfate in a certain amount of water and an organic solvent, conducting heating, then performing cooling to room temperature, and carrying out filtering and standing to precipitate blue acicular crystals. The crystal structure of the complex is determined by single-crystal X-ray, and the chemical formula is [Cu2(FZ)2(H2O)8](SO4)2.4H2O. And the ultraviolet, infrared and antibacterial activity of the complex is further studied. The bacteriostatic activity experimental result shows that the complex has strong bacteriostatic activity on Candida albicans, cryptococcus neoformans, Aspergillus niger and aspergillus terreus, etc. And the complex can be used as an excellent novel bacteriostatic agent product.
Participants received PDT as needed. Additionally, sham IAI injections was administered until week 28. Thereafter, participants received active IAI treatment until week 48.
A method of efficiently expressing Plasmodium AMA-1 ectodomain or a functional part, derivative and/or analogue thereof in a eukaryotic expression system. Preferably, the Plasmodium AMA-1 ectodomain is Pf AMA-1 ectodomain. This protein may be expressed in yeast, such as  Pichia pastoris . Efficient expression is possible using a method for producing mRNA encoding said Plasmodium AMA-1 ectodomain in a yeast cell, comprising providing the yeast cell with a nucleic acid encoding Plasmodium AMA-1 ectodomain, the nucleic acid being modified to utilize the yeast's codon usage. Preferably, at least one putative yeast polyadenylation consensus sequence in the nucleic acid has been modified. More preferably, also at least one site in the protein that is generally glycosylated by eukaryotic expression systems, has been removed.
All enrolled subjects will undergo primary, contiguous 2-level ALIF without supplemental fixation. Control Implant (one-level) implanted with Cellular Bone Matrix (CBM).
Eligible participants will receive initial treatment with pirtobrutinib and obinutuzumab for 12 cycles. Participants with progressive chronic lymphocytuc leukemia or small lymphocytic lymphoma during the off-treatment follow-up will receive continuous pirtobrutinib monotherapy.
The patients were divided into two groups as dry needling and localized vibration using the permuted block randomization method. The study was completed with 20 (17 women, 3 men) in the dry needling group and 20 in localized vibration (15 women, 5 men). In both applications, a total of 3 sessions were made to the patients at 1-day intervals.Patients' age, gender, duration of pain, localization, presence of additional disease, drug use were questioned and recorded. Pressure pain threshold (PPT) was used for the primary outcome measure of the study, and pain intensity, pain tolerance and short form (SF-36) were used for secondary outcome measures. All evaluation criteria except SF-36 were made before, immediately after and 1 day after each session, 1 week after the last session. SF-36 was evaluated before the 1st session treatment, after the 3rd session treatment and 1 week after the 3rd session treatment.
The increasing prevalence of pregnant and postpartum women affected by Opioid Use Disorder (OUD) in the US is highlighted by the growing number of babies referred to the NICU for Neonatal Abstinence Syndrome after birth. Despite recent advances in integrating mental health and substance abuse treatment into adult healthcare settings, no current treatment options exist to integrate maternal OUD treatment and referrals into the pediatric care setting making it unlikely that mothers will be able to access care. In order to preserve the dyadic bond, improve maternal functioning, and provide a more stable environment for the infant after discharge from the NICU, the researchers now embark on a study utilizing steps from intervention mapping to identify facilitators and barriers to integrated maternal OUD treatment and referral in the NICU, adapt existing evidence-based models of co-located OUD care to the NICU setting, and test the feasibility and acceptability of the new model. In Aim 1, the researchers will collect qualitative data via in-depth interviews with 32 NICU providers, social workers, administrators, and parents to determine barriers and facilitators to offering bedside buprenorphine induction and treatment. In Aim 2, the researchers will convene an advisory board to review data collected in Aim 1 and to develop a plan for implementing buprenorphine initiation into the study's unique setting to address the issue- the provision of adult focused OUD care in a pediatric care setting. Aim 2 does not constitute Human Subjects research. The primary outcome of Aim 2 will be a suite of implementation strategies to pilot test in Aim 3. Aim 3 is a pilot case series implementation trial where the researchers will test the adapted intervention to determine feasibility and acceptability to both providers and patients. As this is a case series the investigators propose to recruit 10 participants from each of the two partner NICUs for a total enrollment of N= 20 in Aim 3. A formal sample size calculation was not performed as there is no data on which to a base a formal sample size calculation. For pilot studies with an expected medium standardized effect size, a case number of N= 15 per group has been recommended for pilot studies preceding a possible main study with a power of 90%. The investigators plan to recruit 20 participants to account for possible attrition. The researchers are not necessarily powered to detect an effect. Participants will not be randomized to condition; all NICU mothers meeting inclusion criteria during the study timeline for Aim 3 will be invited to participate in Aim 3. The outcomes of acceptability and feasibility will be measured through questionnaires, interviews, and treatment initiation and retention statistics.
FIELD: veterinary. SUBSTANCE: proposed vaccine contains virus tissue filtrate of smallpox strain of sheep having biological activity 4.0-6.5 lg ID 50/0,2ml  and stabilizing agent at ratio 40-60/40-60. Skimmed milk or gelatin-saccharose medium is used as stabilizing agent. Mentioned above strain is adapted to subcutaneous sheep fat. Proposed vaccine has high immunogenic activity, it is harmless for epicutaneous, intracutaneous, subcutaneous, intramuscular, intranasal and intravenous injection. Period of immunity is 18 months or more. EFFECT: increases immunogenic activity of vaccine and simplifies its production. 2 tbl
Sensorineural hearing loss accounts for about 90% of all hearing loss and is found in 23% of individuals older than 65 years. Sensorineural hearing loss occurs when the hair cells of the inner ear and the neural pathways to the auditory cortex are damaged. In most cases, sensorineural hearing loss cannot be improved, reversed or 'cured.' Current treatment options focus on methods that amplify external sounds and on teaching the patient various strategies to 'retrain' the brain to interpret external stimuli. Low Level Laser Therapy was first applied for the treatment of inner ear diseases by Uwe Witt, MD of Hamburg, Germany in the 1980's. Hearing impaired patients have inflammation and/or atrophy of the tissues and neural pathways connected to and supporting the cochlea's cilia hair structure, the hearing mechanism of the inner ear. Low level laser therapy is believed to stimulate the mitochondria of the adipocyte cells, which subsequently increases the production of ATP. The resultant surge in ATP production works to repair damaged tissue and regenerate cells reversing some of the damage incurred to the cochlea and thus improving aspects of hearing function.
PROBLEM TO BE SOLVED: To obtain an erection dysfunction remedy having the activity to increase the level of cyclic guanosine monophosphate declined in production by NG-monomethyl-L-arginine or the like including symmetry-NG,N'G-dimethyl-L- arginine as effective ingredient. SOLUTION: This remedy is obtained by including, as effective ingredient, symmetry-NG,N'G-dimethyl-L-arginine(SDMA) or a salt thereof (e.g. hydrochloride, acetate), optionally in combination with sildenafil citrate salt or the like. To prepare this remedy in the form of a solid oral preparation, a vehicle, binder, disintegrant, etc., are added. As for the method for administrating this remedy, it is administered pref. 30 min to one hour before desiring penis erection, its dose being appropriately 5-100 mg at a time orally; it is recommended that in the form of a patch, e.g. a tape containing SDMA (salt) at 1-50 mg/cm2 is used; and in the form of a liniment, e.g. an ointment, cream containing SDMA (salt) at 1-100 mg/g.
Two patients with thyroid eye disease underwent inferomedial orbital decompression complicated by a cerebrospinal fluid (CSF) leak. One of the cases developed a postoperative pneumocephalus resolved with conservative measures. In the second case, the CSF leak was managed intraoperatively. In both patients, a computed tomography (CT) scan revealed a pronounced slope of the lateral lamella of the cribriform plate, forming an obtuse angle with its lateral bony extension. When this anatomical disposition of the olfactory fossa (OF) is present, the course of the anterior ethmoidal artery (AEA) is usually embedded in the skull base, and its foramen should not be taken as the upper limit of the transconjunctival ethmoidectomy. The shape and relative height of the olfactory fossa and fovea ethmoidalis, and the course of the AEA should always be assessed before transconjunctival medial decompressions.
BACKGROUND: Recently shown to regulate cardiac development, the secreted axon guidance molecule SLIT3 maintains its expression in the postnatal heart. Despite its known expression in the cardiovascular system after birth, SLIT3's relevance to cardiovascular function in the postnatal state remains unknown. As such, the objectives of this study were to determine the postnatal myocardial sources of SLIT3 and to evaluate its functional role in regulating the cardiac response to pressure overload stress.
METHODS: We performed in vitro studies on cardiomyocytes and myocardial tissue samples from patients and performed in vivo investigation with SLIT3 and ROBO1 (roundabout homolog 1) mutant mice undergoing transverse aortic constriction to establish the role of SLIT3-ROBO1 in adverse cardiac remodeling.
RESULTS: We first found that SLIT3 transcription was increased in myocardial tissue obtained from patients with congenital heart defects that caused ventricular pressure overload. Immunostaining of hearts from WT (wild-type) and reporter mice revealed that SLIT3 is secreted by cardiac stromal cells, namely fibroblasts and vascular mural cells, within the heart. Conditioned media from cardiac fibroblasts and vascular mural cells both stimulated cardiomyocyte hypertrophy in vitro, an effect that was partially inhibited by an anti-SLIT3 antibody. Also, the N-terminal, but not the C-terminal, fragment of SLIT3 and the forced overexpression of SLIT3 stimulated cardiomyocyte hypertrophy and the transcription of hypertrophy-related genes. We next determined that ROBO1 was the most highly expressed roundabout receptor in cardiomyocytes and that ROBO1 mediated SLIT3's hypertrophic effects in vitro. In vivo, Tcf21+ fibroblast and Tbx18+ vascular mural cell-specific knockout of SLIT3 in mice resulted in decreased left ventricular hypertrophy and cardiac fibrosis after transverse aortic constriction. Furthermore, α-MHC+ cardiomyocyte-specific deletion of ROBO1 also preserved left ventricular function and abrogated hypertrophy, but not fibrosis, after transverse aortic constriction.
CONCLUSIONS: Collectively, these results indicate a novel role for the SLIT3-ROBO1-signaling axis in regulating postnatal cardiomyocyte hypertrophy induced by pressure overload.
Methylene blue (MB) with a concentration of 10 mg/mL was delivered inside the periodontal pocket. MB was injected inside in the selected periodontal pockets 4 - 6 mm with the help of a blunt needle and left for 1 min. Later, the periodontal pockets were flushed with distilled water for 3 min to remove the excess MB. The diode laser HELBO® TheraLite - Bredent Medical, Germany) of diameter 200 µm was used to deliver the light to initiate the disinfection process. Each participant underwent single session of laser exposure. The laser parameters such as wavelength, spot area, power output and laser energy were set at 660 nm, 0.028 cm2, 60 mW/cm2, and 150 mW, respectively. The laser was subjected for a period of 30 s in each pocket.
Kefir group received one bottle of kefir (180 ml) daily for 12 weeks. Microbial composition of the kefir included Lactococcus lactis ssp. lactis, Lactococcus lactis ssp. cremoris, Lactococcus lactis ssp. diacetylactis, Leuconostoc mesenteroides ssp. cremoris, Lactobacillus kefyr, Kliyveromyces marxianus, and Saccharomyces unisporus.
The present invention discloses a traditional Chinese medicine composition for treatment of swollen sore throat. The traditional Chinese medicine composition comprises, by weight, 3-4 parts of cimicifuga foetida, 7-9 parts of groundnut leaf, 3-5 parts of radix codonopsis, 2-4 parts of adenophora root, 5-7 parts of white peony root, 10-12 parts of balloonflower root, 7-9 parts of honey-fried licorice root, 4-6 parts of fructus forsythia, 2-4 of parts Arabian jasmine flower, 1-2 parts of Chinese paris rhizome, 10-15 parts of mulberry leaf, 2-3 parts of Berchemia yunnanensis Franch, 2-4 parts of ahyranthes aspera, 1-3 parts of heydyotis, 2-4 parts of plygala japonica, 2-4 parts of lspedeza pilosa and 1-3 parts of autilon indicum seet. The components of the traditional Chinese medicine composition are combined by based on an overall analysis of the illness and the patient's condition. Traditional Chinese medicine composition has effects of softening hardness and dissipating binds, activating blood and dissipateing phlegm, clearing away heat and toxic, diminishing swelling and restoring the voice. The traditional Chinese medicine composition is mainly used for acute or chronic swollen sore throats. The traditional Chinese medicine composition has a quick result and good curative effect, and the total effective rate achieves 97.5%.
Groin pain syndrome (GPS) is a controversial topic in Sports Medicine. The GPS Italian Consensus Conference on terminology, clinical evaluation and imaging assessment of groin pain in athletes was organized by the Italian Society of Arthroscopy in Milan, on 5 February 2016. In this Consensus Conference (CC) GPS etiology was divided into 11 different categories for a total of 63 pathologies. The GPS Italian Consensus Conference update 2023 is an update of the 2016 CC. The CC was based on a sequential, two-round online Delphi survey, followed by a final CC in the presence of all panelists. The panel was composed of 55 experts from different scientific and clinical backgrounds. Each expert discussed 6 different documents, one of which regarded the clinical and imaging definition of sports hernias, and the other 5 dealt with 5 new clinical situations thought to result in GPS. The panelists came to an agreement on the definition of a sports hernia. Furthermore, an agreement was reached, recognizing 4 of the 5 possible proposed pathologies as causes to GPS. On the contrary, the sixth pathology discussed did not find consensus given the insufficient evidence in the available scientific literature. The final document includes a new clinical and imaging definition of sports hernia. Furthermore, the etiology of GPS was updated compared to the previous CC of 2016. The new taxonomic classification includes 12 categories (versus 11 in the previous CC) and 67 pathologies (versus 63 in the previous CC).
This is an international proposal consisting of two projects with synergistic aims that will be carried out in a joint effort by the National Aeronautics and Space Administration (NASA) and the German Aerospace Center (DLR) as well as the European Space Agency (ESA). The project targets NASA's particular interest in studying the 'Cognitive-perceptual-visuospatial brain domain changes due to isolation and confinement' as part of the Complement of Integrated Protocols for Human Exploration Research (CIPHER) project on the International Space Station (ISS). The collected data will demonstrate whether prolonging mission duration to one year will have detrimental effects on general cognitive performance (measured with the Cognition test battery), spatial cognition, structural and functional brain changes in general, and hippocampal plasticity more specifically relative to the shorter 6-month and 2-month ISS missions. Using state-of-the-art neuroimaging techniques, investigators will determine the biological basis for any changes in cognitive performance, with a focus on hippocampal plasticity and spatial cognition. Similar data already gathered on the ISS and in several short- and long-duration space analog environments will be used to generate a normative data base for long-duration missions. Finally, investigators will derive dose-response relationships between cognitive-visuospatial brain domain changes and mission duration that will allow predicting vulnerability to adverse cognitive or behavioral impairment and psychiatric disorders on interplanetary expeditions such as a mission to Mars. The two projects will deliver a highly unique and comprehensive set of integrated neuroimaging and neurocognitive tools for the evaluation and ultimately prevention of adverse effects on brain structure and function that lead to behavioral effects associated with exploration-type missions.
BACKGROUND AND OBJECTIVES: With the discovery of the potential role of gait and eye movement disorders in Parkinson's disease (PD) recognition, we intend to investigate the combined diagnostic value of gait and eye movement disorders for PD.
METHODS: We enrolled some Chinese PD patients and healthy controls and separated them into the training and validation sets based on enrollment time. Performance in five oculomotor paradigms and in one gait paradigm was examined using an infrared eye tracking device and a wearable gait analysis device. We developed and validated a combined model for PD diagnosis via multivariate stepwise logistic regression analysis. Furthermore, subgroup comparisons and multi-model comparison were performed to assess its applicability and advantages.
RESULTS: A total of 145 PD patients and 80 healthy controls in China were recruited. The pro-saccade velocity, the trunk-sway max, and the turn mean angular velocity were finally screened out for the model development. Incorporating age factor, the ternary model demonstrated more satisfactory performance on ROC (AUC of 0.953 in the training set and AUC of 0.972 in the validation set), calibration curve, and decision curve. A nomogram was drawn to visualize the model. The combined model outperforms individual models with a broad application and the unique diagnostic value for early detection of PD patients, especially TD-PD patients.
CONCLUSION: We demonstrated the presence of gait and eye movement disorders, as well as the feasibility, applicability, and superiority of employing them together to diagnose PD.
Promacta® is commercially available in 12.5 mg, 25 mg, 50 mg, and 75 mg tablets. For this study, for young children unable to swallow a tablet, eltrombopag powder for oral suspension (Eltrombopag PfOS) will be used. PfOS is only available for investigational use at 20mg. Each sachet contains eltrombopag equivalent to 20mg per gm of powder and is reconstituted to a total of 10 ml so that the concentration is 2 mg/ml.
FIELD: organic chemistry, medicine, gastroenterology, pharmacy. SUBSTANCE: invention relates to novel derivative of benzoxazole of the general formula (I)   or its salt where R 1  represents chlorine atom; R 2  represents hydrogen atom; R 3  represents methyl group. Invention relates also to a medicinal agent showing antagonistic effect with regard to serotonin receptors 5-HT 3 , and containing compound of the formula (I) or its pharmaceutically acceptable salt and pharmaceutical addition. Invention relates also to method of prophylactic and/or therapeutic treatment of patients with state of irritable bowel syndrome or functional gastroenteric tract disturbance or diarrhea state that involves administration in mammal by prophylactic and/or therapeutical schedule compound of the formula (I) or its pharmaceutically acceptable salt in effective dose. Compound of the formula (I) can be used as antagonist of serotonin receptors 5-HT 3  or as partial activating agent of serotonin receptors 5-HT 3 . Invention provides synthesis of novel compound exhibiting antagonistic effect with regard to serotonin receptors 5-HT 3 . EFFECT: improved method of treatment, valuable medicinal properties of compounds. 5 cl, 4 tbl, 34 ex
PURPOSE: A mixed micelle containing retinyl palmitate, phospholipid, polyhydric alcohol, surfactant, ethanol, and purified water is provided to produce a cosmetic product. CONSTITUTION: A mixed micelle contains 0.01-10.0 wt% of retinyl palmitate, 1.0-10.0 wt% of phospholipid, 1.0-50.0 wt% of polyhydric alcohol, 1.0-10.0 wt% of surfactant, 1.0-50.0 wt% of ethanol, and purified water. The phospholipid is lecithin, hydrolecithin, lysolecithin, or hydroxylated lecithin. The lecithin is phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidyl serine, or phosphatidyl glycerin. The polyhydric alcohol is glycerin, butylenes glycol, propylene glycol, or dipropylene glycol. A cosmetic composition with improved stability of retinyl palmitate contains 0.1-10.0 wt% of the mixed micelle.